norvancomycin

Norvancomycin is a glycopeptide antibiotic closely related to vancomycin, differing by a single methyl group. It was first isolated from Amycolatopsis orientalis and has been used clinically in China since the late 1960s. Norvancomycin acts by inhibiting bacterial cell wall synthesis, making it effective against resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Its primary indications include severe infections such as endocarditis, osteomyelitis, pneumonia, sepsis, and soft tissue infections caused by susceptible organisms. Norvancomycin is typically administered intravenously[1][2][5][7].

Brand names

norvancomycin

Other names

desmethylvancomycin56-demethylvancomycin